T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation
Evaluating Immunogenicity Risk Due to Host Cell Protein Impurities in Antibody-Based Biotherapeutics
Clinical validation of the “in silico” prediction of immunogenicity of a human recombinant therapeutic protein
Clinical validation of the “in silico” prediction of immunogenicity of a human recombinant therapeutic protein Scios Inc, Brown University, Amgen Clinical Immunology (2007). [ISPRI prediction of immunogenicity]